WARSAW, Ind., Feb. 5, 2016 /PRNewswire/ -- Zimmer Biomet
Holdings, Inc. (NYSE and SIX: ZBH) today announced the pricing of
the previously announced underwritten secondary offering of
11,027,558 shares of its common stock by certain of its
stockholders, consisting of affiliates of Blackstone and Goldman
Sachs. The shares are being sold to the public at an initial
price of $96.45 per share. The
selling stockholders will receive all of the proceeds of the
offering. Neither Zimmer Biomet nor any of its directors,
officers or other stockholders is selling any shares of common
stock in the offering. The closing of the offering is expected to
occur on February 10, 2016, subject
to the satisfaction of customary closing conditions.
Subject to the closing of the offering, Zimmer Biomet will
purchase from the underwriter $250
million of the shares of common stock being sold by the
selling stockholders at a price per share equal to the weighted
average per share purchase price payable by the underwriter to the
selling stockholders.
Barclays Capital Inc. is acting as the sole underwriter for the
offering.
Zimmer Biomet has filed a registration statement (including a
base prospectus) with the U.S. Securities and Exchange Commission
(the "SEC") relating to these securities. The offering of
these securities was made only by means of a written prospectus
forming part of the effective registration statement. The
base prospectus and the preliminary prospectus supplement have been
filed with the SEC and are available on the SEC's website at
http://www.sec.gov. A copy of the final prospectus supplement
related to the offering will be filed with the SEC, and may be
obtained, when available, from Barclays Capital Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, Email:
Barclaysprospectus@broadridge.com, Telephone: (888) 603-5847.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor will there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global
leader in musculoskeletal healthcare. We design, manufacture
and market orthopaedic reconstructive products; sports medicine,
biologics, extremities and trauma products; spine, bone healing,
craniomaxillofacial and thoracic products; dental implants; and
related surgical products.
Zimmer Biomet collaborates with healthcare professionals around
the globe to advance the pace of innovation. Its products and
solutions help treat patients suffering from disorders of, or
injuries to, bones, joints or supporting soft tissues.
Together with healthcare professionals, Zimmer Biomet helps
millions of people live better lives.
Zimmer Biomet has operations in more than 25 countries around
the world and sells products in more than 100 countries.
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 regarding the underwritten secondary
offering of shares of Zimmer Biomet's common stock, including
Zimmer Biomet's concurrent share repurchase. Forward-looking
statements may be identified by the use of forward-looking terms
such as "may," "will," "expects," "believes," "anticipates,"
"plans," "estimates," "projects," "assumes," "guides," "targets,"
"forecasts," and "seeks" or the negatives of such terms or other
variations on such terms or comparable terminology. Such
statements are based upon the current beliefs and expectations of
management and are subject to significant risks and uncertainties
that could cause actual outcomes and results to differ
materially. For a list and description of some of such risks
and uncertainties, see our periodic reports filed with the
SEC. These factors should not be construed as exhaustive and
should be read in conjunction with the other cautionary statements
that are included in Zimmer Biomet's filings with the SEC. We
disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be set forth in our
periodic reports. Accordingly, such forward-looking
statements speak only as of the date made. Readers of this
communication are cautioned not to place undue reliance on these
forward-looking statements, since, while management believes the
assumptions on which the forward-looking statements are based are
reasonable, there can be no assurance that these forward-looking
statements will prove to be accurate. This cautionary
statement is applicable to all forward-looking statements contained
in this communication.
Logo -
http://photos.prnewswire.com/prnh/20150624/225371LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/zimmer-biomet-holdings-announces-pricing-of-secondary-offering-of-common-stock-and-concurrent-share-repurchase-300215877.html
SOURCE Zimmer Biomet Holdings, Inc.